Cargando…
Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084905/ https://www.ncbi.nlm.nih.gov/pubmed/35547599 http://dx.doi.org/10.2147/CMAR.S372533 |
Ejemplares similares
-
Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment
por: Tong, Jingtao, et al.
Publicado: (2021) -
Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan [Corrigendum]
Publicado: (2021) -
CORRIGENDUM to The mechanisms of acute interstitial nephritis in the
era of immune checkpoint inhibitors in melanoma
Publicado: (2019) -
Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
Publicado: (2022) -
Corrigendum to Serum hepcidin levels in multiple sclerosis
Publicado: (2020)